LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Talia Golan(Sheba Medical Center), Salomon M. Stemmer(Tel Aviv University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Donald Richards(The US Oncology Network), Ravit Geva(Tel Aviv Sourasky Medical Center), Haofei Tiffany Wang(Eli Lilly (United States)), Boris K. Lin(University of Leeds), Richard A. Walgren(Eli Lilly (United States))
Cited by 107
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k